Stock PDPL PARENTERAL DRUGS (INDIA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Parenteral Drugs (India) Limited NSE India S.E.

Equities

PDPL

INE904D01019

Market Closed - NSE India S.E.
Other stock markets
 07:40:39 2023-08-21 EDT 		5-day change 1st Jan Change
2.9 INR +1.75% Intraday chart for Parenteral Drugs (India) Limited -.--% -.--%
2023 PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL CI
2023 NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL
CI
NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs
CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021
CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2021
CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021
CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020
CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020
CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2020
CI
Parenteral Drugs India Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019
CI
Parenteral Drugs Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2019
CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2019
CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019
CI
Parenteral Drugs India Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018
CI
Infutec Healthcare Ltd cancelled the acquisition of Kasrawad and WFI undertakings from Parenteral Drugs Limited.
CI
Parenteral Drugs Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2018
CI
Parenteral Drugs Limited Reports Unaudited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2018
CI
Parenteral Drugs Limited Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2018
CI
Parenteral Drugs Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017
CI
Infutec Healthcare Ltd agreed to acquire the Kasrawad and WFI undertakings from Parenteral Drugs Limited.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDPL Stock
  4. PDPL Stock
  5. News Parenteral Drugs (India) Limited
  6. Highlights